



8 July 2021

IMPACT OF COVID-19 RESTRICTIONS ON THE COMPANY'S ANNUAL GENERAL MEETING

Dear Shareholders,

The shareholder meeting is scheduled to be held at Level 36, Gateway Tower, 1 Macquarie Place, Sydney NSW 2000 on Friday, 16 July 2021 at 12.00pm (AEST) (**Meeting**).

The Company is continuing to monitor the impact of the COVID-19 virus OUTBREAK in New South Wales and is following guidance from the Federal and State Governments. In light of the current circumstances and restrictions on gatherings, the Directors have made the decision to hold the Meeting virtually. There will not be a physical location where shareholders can attend the Meeting in person.

All resolutions at the Meeting will be decided by poll, based on votes submitted by proxy and at the Meeting by shareholders who have indicated that they intend to vote at the Meeting in accordance with the instructions set out below.

The Directors instruct all shareholders who would like to have their vote counted to either:

- (a) vote by lodging a proxy form prior to 14 July 2020 at 12.00pm (AEST); or
- (b) Shareholders who wish to participate and vote at the Meeting should contact the Company at nicholas.ong@minervacorporate.com.au prior to 14 July 2021 at 12.00pm (AEST) at which point the Company will email you a personalised poll form for the purpose of voting on a poll at the Meeting.

How Shareholders can participate:

- (a) Shareholders are strongly urged to appoint the Chair of the Meeting as their proxy. Shareholders can complete the proxy form to provide specific instructions on how a Shareholder's vote is to be cast on each item of business, and the Chair of the Meeting must follow your instructions. Lodgement instructions (which include the ability to lodge proxies online) are set out in the Proxy Form attached to the Notice of Meeting. If a person other than the Chair is appointed as proxy, the proxy will

revert to the Chair in the absence of the appointed proxy holder's attendance at the meeting.

- (b) Shareholders who intend to participate and vote on a poll at the Meeting must contact the Company at Nicholas.ong@minervacorporate.com.au notifying the Company that you intend to participate and vote on a poll at the Meeting by emailing the Company a poll form. You will also need to register and access the Shareholder Meeting by videoconference to follow the meeting and timing of the poll (see paragraph (e) below). After giving notice and after 14 July 2021 at 12.00pm (AEST), the Company will send you a **ZOOM Video Conferencing** link and personalised poll form. The personalised poll form must be completed and returned to the Company after the poll has been called and prior to the close of polling. During the Meeting, the Chair will notify you when and how you are able to complete and return the personalised poll form. The results of the Meeting will then be announced on the same day.
- (c) Shareholders who have completed a proxy form but have not notified the Company that you intend to participate and vote on a poll at the Meeting will have an opportunity to participate in the Meeting through the videoconference facility described in paragraph (e) below. In this circumstance, the person you have appointed as proxy will cast your vote on your behalf.
- (d) Shareholders are also invited to submit questions in advance of the Meeting by email to the Company Secretary at Nicholas.ong@minervacorporate.com.au. Responses will be provided at the Meeting in respect of all valid questions received prior to 14 July 2021 at 12.00pm (AEST). Shareholders who attend the video conference will be given the opportunity to ask questions during the meeting.

The Notice of Meeting can be viewed and downloaded from the link set out below.

<https://www.nsx.com.au/ftp/news/021739630.PDF>

The Company appreciates the understanding of its Shareholders as it navigates this difficult situation.

Nicholas Ong
Company Secretary

-###-

About Beroni Group Limited

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialisation of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.

Forward-Looking Statements Disclaimer

This press release contains forward-looking statements or forward-looking information, within the meaning of applicable United States and Australian securities laws with respect to the Company. By their nature, forward-looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements. Generally forward-looking statements can be identified by the use of terminology such as “anticipate”, “will”, “expect”, “may”, “continue”, “could”, “estimate”, “forecast”, “plan”, “intend”, “believe”, “potential” and similar expressions.

Forward-looking information contained in this press release is based on Company management’s opinions, estimates and assumptions in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward-looking statements involve significant risks, uncertainties and assumptions, and there can be no assurance that such statements, or its underlying risks, uncertainties and assumptions will prove to be accurate. Factors that could cause actual results or events to differ materially include, without limitation, risks related to laws, rules and regulation applicable to the Company as well as the industry in which it operates (including in respect of taxes and other levies), economic or market conditions on both a national and global level, currency fluctuations, risks inherent to other entities at a similar stage of development and industry in which the Company currently is, competition from the Company’s competitors, unsatisfactory development or marketing of the Company and/or its products or services, regulatory action or litigation (including product liability claims), and failure to enter into agreements or arrangements with other parties on fair or reasonable terms. Forward-looking information is made only as of the date on which it is provided and, except as may be required by applicable laws, the Company disclaims any intent or obligation to update such forward-looking information whether as a result of new information, future events or otherwise.

For further information, please contact us at:

Phone: +61 2 8051 3055

Email: enquiry@beronigroup.com

Website: www.beronigroup.com